Zacks Investment Research downgraded shares of MIMEDX GRP INC (MDXG) from OUTPERFORM to NEUTRAL on December 16, 2014, with a target price of $12.20.
MiMedx Group, Inc. ("MiMedx Group") is a development stage company that integrates, develops and manufactures patent protected biomaterial-based products for the Orthopedics and Spine market categories. The Company's two proprietary biomaterials are collafix and hydrofix, which are applied in the treatment of traumatized tissue and structures. The collafix products are assembled from a strong, collagen-fiber based technology that can be used to augment the repair of soft-tissue and connective tissue injuries. The hydrofix products are constructed of durable hydrogel, a water-based biomaterial, that find their use in spinal and orthopedic applications, Its products include Hydrofix Vaso Shield, indicated as a cover for vessels following anterior vertebral surgery and Hydrofix Spine Shield, an adhesion barrier for use as a spine cover after vertebral surgery. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MIMEDX GRP INC (MDXG),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment